Compound ID | 8

Update compound information

Suvratoxumab

Synonym(s): MEDI4893  |  LC-10  |  LC10

Class: Antibody

Agent Type: Indirect acting; Antibody;
Spectrum of activity: Gram-positive
Mechanism of action: Neutralises Staphylococcus aureus α-toxin (Hla); blocks α-toxin binding to its cell receptor and prevents formation of the lytic heptameric transmembrane pore.
Target Pathogen: Active against Staphylococcus aureus
Combined with other compounds: Yes
Institute where first reported: Medimmune, USA
Year first mentioned: 2012
Highest development stage: Phase 3 (NCT05331885)
Development status: Inactive
Reason dropped: Administrative reasons
External links:
PubChem link: https://pubchem.ncbi.nlm.nih.gov/substance/472405028
Guide to Pharmacology: suvratoxumab
Citations:
  • http://aac.asm.org/content/59/1/299.full
  • https://clinicaltrials.gov/ct2/show/NCT02296320?term=MEDI4893&rank=1
    • Patents:
  • WO2012109285
  • US20140072577A1
  • WO2017075188
    		•

    AntibioticDB is supported by GARDP.

    If you have feedback, experience problems, or are interested in a collaboration, please contact us. | Terms and conditions

    The content of this site is intended for educational and scientific research purposes only and not as a source of medical advice or consultation.